Table 2 The efficacy and safety of novel CAR T-cells

ssCART−19

47

Fludarabine at 30mg/m²/day, cyclophosphamide at 300mg/m²/day on D−5,−4, and−3

Grade 1–2

25/47 (53.20%) Grade 3–4

7/47 (14.89%)

Grade 1

2/47 (4.26%)

91.49% CR/CRi on day 28

mPFS

14.7 months

N/A

[5]

WZTL−002

21

Fludarabine (30 mg/m²/day) and cyclophosphamide (500mg/m²/day) on D−5,−4, and−3

Grade 1–2

13/21 (62%)

No ICANS of any grade

52% CR at 3 months

N/A

N/A

[6]

19(T2)28z1XX

28

Fludarabine and cyclophosphamide

Grade 1–2

24/28 (86%)

Grade 3

1/28 (4%)

Grade 1–2

1/28 (4%)

Grade 3

2/28 (7%)

82% ORR

71% CR

N/A

N/A

[7]

BRL−201

21

Cyclophosphamide (500mg/m², D−3 to−2) and fludarabine (30mg/m², D−4 to−2)

Grade 1–2

14/21 (66.7%)

Grade 1–2

4/21 (19.0%)

100% ORR

85.7% CR

mPFS

20.8 months

76.2% 12-month OS

[8]

UCART20×22

3

Fludarabine 30 mg/m² × 3d, cyclophosphamide 0.5 g/m² × 3d, alemtuzumab 12 mg on D1, 24 mg on D2, D3

Grade 1–2

3/3 (100%)

No ICANS of any grade

66.7% CR on day 28

N/A

N/A

[9]

CD19/CD70 CAR T-cells

8

Cyclophosphamide and fludarabine chemotherapy conditioning 1–2 days

Grade 1–2

3/8 (37.5%)

No ICANS of any grade

87.5% ORR

75.0% CR

at 1 month

N/A

N/A

[10]

C-CAR039

48

Cyclophosphamide plus fludarabine chemotherapy conditioning 3 days

Grade 1–2

44/48 (91.7%)

Grade 3

1/48 (2.1%)

Grade 1–2

3/48 (6.52%)

91.5% ORR

85.1% CR

66.0%

24-month PFS

77.9%

24-month OS

[11]

ONCT−808

N/A

Cyclophosphamide and fludarabine

N/A

N/A

N/A

N/A

N/A

[12]